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The regulation of vascular resistance is critical to the maintenance of circulatory ho- 
meostasis. The primary regulator of this resistance is the level of contraction of vascular 
smooth muscle, which is determined by the balance of factors that cause contraction with 
those that cause relaxation of this muscle. This review will feature the latter. However, 
to do this in a meaningful manner, specific contractile factors will also be considered. 
Under physiological conditions, vascular smooth muscle (VSM) contraction requires a 
concentration of ionized calcium ([Ca2']J in the cytosol greater than M and an 
energy source, ATP. Normally, [Ca2+Ii is the regulated variable that determines the 
magnitude of contraction (VSM tone). Relaxation is effected by mechanisms represented 
in Fig. 1 that reduce [Ca2+Ii and are therefore relevant to this review. Two of the 
mechanisms utilize active pumps requiring energy from ATP to move calcium out of the 
cytosol against large concentration gradients. These are the ATPase of the calcium efflux 
pump in the plasma membrane and the ATPase that sequesters calcium into the sarco- 
plasmic reticulum (SR). The third calcium-lowering mechanism is the sodium<alcium 
exchanger. This exchanger couples the energy derived from the movement of sodium 
down its concentration gradient into the cell to the extrusion of calcium from the cell. 
The concentration of ionized calcium inside the cell is a net value determined by the 
relative rates of calcium movement into the cell and the sum of the activities of these three 
[Ca2+Ii-lowering mechanisms. The nature of this balance indicates yet another means by 
which [Ca2+Ili may be reduced to produce VSM relaxation. This is obviously a reduction 
in the rate of calcium entry into the cytosol, as would result from the action of a calcium 
channel antagonist, or, indirectly, by hyperpolarization of the plasma membrane or in- 
terference with other calcium delivery systems. 
CYCLIC NUCLEOTIDES 
Cyclic nucleotides are second messengers that play an important role in regulating 
[Ca2+Ii. They accomplish this regulation through their influence on the mechanisms listed 
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FIG. 1. Mechanisms by which cytosolic [Ca”], is lowered to produce vascular smooth muscle relaxation 
include extrusion through the plasma membrane, sequestration into the sarcoplasmic reticulum (SR), and the 
sodiumkalcium exchanger. Cytosolic [CaZ*], can also be lowered by decreasing the rate of entry of calcium 
using calcium channel antagonists or potassium channel openers. The latter produce plasma membrane hyper- 
polarization, closing voltage-sensitive calcium channels. 
in the preceding paragraphs. Their importance in this and other regulatory roles was 
recognized by the award of the Nobel Prize in 1971 to Dr. Earl Sutherland for the 
discovery of cyclic adenosine monophosphate (CAMP) in 1957 (62). 
These second messengers are remarkably diverse in their regulation of cellular func- 
tions, yet all of their actions are mediated by their activation of protein kinases. These are 
enzymes that transfer a phosphate group from ATP to another protein. This phosphory- 
lation changes the activity of the second protein, causing the cellular response (secretion, 
contraction, or lowering of [Ca2+Ii depending on the specialized function of the protein 
that was phosphorylated). 
The first of these cyclic nucleotides to be studied extensively was CAMP. This cyclic 
nucleotide is produced intracellularly from ATP by the activated enzyme adenylate cy- 
clase. Activation of this enzyme, therefore, becomes the important means by which this 
second messenger is produced. Of particular relevance to the regulation of VSM is the fact 
that P-adrenergic receptors of this muscle activate adenylate cyclase. Catecholamines that 
bind to these receptors cause an accumulation of cAMP in the cell, followed by relaxation 
of VSM. Adenosine, arising from metabolic activity of the parenchyma, is an important 
paracrine messenger that also causes VSM relaxation by activating adenylate cyclase to 
produce cAMP (42). Interesting observations have been made bearing on the possible 
mechanism by which cAMP causes this relaxation. 
One of these mechanisms involves a deactivation of the basic process by which the 
contractile proteins cause contraction. Rembold and Murphy (56) established that myosin 
light chain (MLC) (a 20 kDa protein) phosphorylation is necessary and sufficient for 
contraction of this smooth muscle. It follows that dephosphorylation would inevitably 
lead to relaxation. This phosphorylation is caused by the calciumxalmodulin-dependent 
enzyme, myosin light chain kinase (MLCK). This enzyme in turn can be phosphorylated 
by a cyclic AMP-dependent kinase and when MLCK is phosphorylated, its activity is 
decreased. Adelstein has presented extensive evidence (2) supporting the hypothesis that 
cAMP causes relaxation by this deactivation of MLCK with the resultant decreased 
phosphorylation of MLC . 
Gerthoffer et al. (24) presented evidence indicating that although cAMP may facilitate 
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relaxation by dephosphorylating MLC, this is not the primary mechanism by which cAMP 
produces relaxation. They studied relaxation of phenylephrine-contracted VSM following 
rinsing of phenylephrine from the bath. The relaxation was normally slow, being incom- 
plete 15 min after the bath had been rinsed. Yet they had determined that MLC was 
completely dephosphorylated 2 min after the rinse, corresponding to the time when 
[Ca2+Ii had returned to the resting level. Adding forskolin (an activator of adenylate 
cyclase) to the bath during the slow relaxation following this 2 min period caused a great 
increase in the rate of relaxation (Fig. 2). They argue that the elevated levels of cAMP 
caused by the addition of forskolin could not have caused this relaxation by phosphory- 
lating and inactivating MLCK because the light chain was already completely dephos- 
phorylated. Cyclic AMP must act through another mechanism to produce this relaxation. 
They suggest that this relaxation results from the activation of another CAMP-dependent 
kinase that activates a substrate protein capable of lowering the residual slightly elevated 
[Ca2+Ii responsible for delaying the relaxation. This phosphorylated substrate could be 
any one of the three calcium handling systems illustrated in Fig. 1 that are capable of 
lowering [Ca2+Ii. Alternatively, the substrate could be a potassium channel protein, the 
activation of which would result in hyperpolarization, thereby decreasing calcium influx. 
Yet another mechanism of relaxation by cyclic nucleotides has recently received sup- 
porting evidence. This is an inactivation of the sequence of events whereby a vasocon- 
strictor agonist causes an increase in cytosolic calcium. When the agonist binds to its 
specific membrane receptor, the receptor activates a G protein in the membrane that in 
turn activates the enzyme phospholipase C, which cleaves phosphoinositide into inositide 
trisphosphate (IP,) and diacylglycerol. IP, escapes into the cytosol and causes the release 
of calcium from the SR. Rapoport et al. (53) reported that the inhibition by cyclic 
nucleotide of a norepinephrine (NE) -induced contraction of VSM was accompanied by a 
decrease in inositide phosphate production. Hirata et al. (28) elaborated on this observa- 
tion, demonstrating that the inhibition resulted from a phosphorylation that inactivated the 
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FIG. 2. The effect of forskolin (activator of adenylate cyclase) on relaxation after phenyleprine (PE) washout. 
Control relaxations (n  = 4) were obtained after 15-min contractions with PE. Forskolin was added (dashed line) 
2 min after PE washout at a time when the myosin light chain was already dephosphorylated. Reprinted from 
ref. 24 with permission. 
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G protein so that phospholipase C was no longer activated. Cyclic guanosine monophos- 
phate (cCMP) was far more active than cAMP in producing this inhibition. 
An ingenious study by Lincoln et al. (38) has recently shifted the focus of the mech- 
anism of action of forskolin from cAMP to cGMP. These investigators monitored the 
increased [Ca” 1, caused by arginine-vasopressin (AVP) in cultured rat aorta cells. They 
observed that in cells from primary cultures, this response was depressed following 
activation of adenylate cyclase with forskolin or with a P-adrenergic agonist. However, 
they also observed that if this study were carried out on cells after multiple passages, 
forskolin potentiated the increase in [Ca2’], caused by AVP. They hypothesized that this 
shift in response to forskolin was brought about by the loss of cGMP-dependent protein 
kinase with multiple passages. They tested this hypothesis by reloading these cells with 
cGMP-dependent protein kinase (using a technique of osmolarity changes to get the 
kinase into the cell). Once the cells were reloaded, they regained their depressant response 
to forskolin. They suggested that cAMP can activate cGMP-dependent kinase and present 
the sequence shown in Fig. 3 .  They conclude that “CAMP can produce both increases in 
Ca2’ levels and decreases in Ca” levels, depending on the absence or presence of 
cGMP-dependent protein kinase in  the cell. ” 
Francis et al. (21) came to a similar conclusion regarding the importance of cGMP from 
a study of many analogues of cAMP and cGMP. They compared the ability of each of the 
analogues to produce relaxation of the pig coronary artery to its ability to activate purified 
cGMP-dependent or CAMP-dependent protein kinases. The very close correlation be- 
tween relaxation and activation of cGMP-dependent protein kinase supported a role for 
cGMP kinase but not for cAMP kinase in decreasing smooth muscle contraction. 
The discovery and characterization of cGMP followed that of cAMP by about one 
decade. In 1963, it  was discovered in rat urine (3)  and its role in smooth muscle relaxation 
was identified in 1977 (32). By 1986. when Murad (43) reviewed the subject, it was 
recognized as the most important second messenger involved in VSM relaxation. Both the 
endothelium-derived relaxing factor (EDRF) and the atrial natriuretic factor (ANF) were 
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FIG. 3. Model for activation of cGMP-dependent protein kinase by CAMP, ANF, atrial natriuretic factor; 
EDRF. endothelium-derived relaxing factor. Reprinted from ref. 3X with permission. 
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found to produce relaxation by activation of guanylate cyclase and the production of 
cGMP. Pharmacologically, a large number of agents, the “nitrovasodilators,” were 
found to produce their effects by the formation of reactive nitric oxide, which increased 
cGMP synthesis. 
The increased production of cGMP initiated by these physiological and pharmacolog- 
ical stimulators of guanylate cyclase is accompanied by a decrease in [Ca2+Ii. Without 
knowing the exact mechanism of this action of cGMP, it is safe to assume that the 
decrease in [Ca2+Ii results from the action of a cGMP-dependent protein kinase. It is not 
known which protein is phosphorylated by this enzyme, and the details of the mechanism 
by which cellular function is altered to cause a decrease in [Ca2+Ii remain undefined. 
Characterization of this cellular function is the information most needed to understand the 
mechanism of VSM relaxation. 
HYPOXIC VASODILATION 
Hypoxic vasodilation is an important condition responsible for VSM relaxation in both 
the physiological regulation and pathophysiological effects on blood flow. Physiologi- 
cally, hypoxia develops when the blood flow to an organ fails to meet the energy re- 
quirements of the organ. The resultant hypoxic vasodilation increases blood flow, tending 
to correct the imbalance. Pathophysiologically, this type of VSM relaxation occurs with 
abnormal deprivation of flow, such as in coronary or cerebral artery occlusion. 
Adenosine triphosphate (ATP) provides the energy required for chemomechanical 
transduction by the contractile proteins. It seems reasonable to expect that hypoxic va- 
sodilation results from an inadequate aerobic production of this energy source. Experi- 
mental observations have established that the mechanism is not this simple. 
The chemomechanical transduction, measured by the velocity of isotonic shortening, 
falls to 50% in smooth muscle when the ATP concentration is reduced to 0.1 mM (27). 
This observation is in accord with the findings of Moreland et al. (41) that force devel- 
opment by the nonphysiological stimulus, 50 mM KC1, was reduced to 50% when the 
ATP concentration had fallen to 0.1 mM. When, instead of KCl, the contraction was 
caused by the physiological agonist norepinephrine (NE), the force had already fallen to 
50% when the ATP concentration was still at the higher level of 0.58 mM. These 
observations lead to two conclusions: (a) mechanisms of hypoxic relaxation differ de- 
pending on whether the contraction is caused by KCl or by NE, and (b) the rate-limiting 
mechanism for a hypoxic relaxation of NE-induced contraction of VSM cannot be the 
actomyosin ATPase activity of the chemomechanical transducer, because, as noted 
above, actomyosin ATPase operates at a half-maximum level when the ATP concentra- 
tion is much lower, i.e., 0.1 mM. 
Moreland et al. (41) evaluated other mechanisms that may be responsible for the VSM 
relaxation caused by hypoxia. They presented these in their model (Fig. 4) that depicts 
other energy-requiring processes, possibly responsible for hypoxic vasodilation. 
Energy in the form of ATP is required for the active removal of Ca2+ from the cytosol. 
However, curtailing by hypoxia the activities of these pumps that extrude or sequester 
Ca2+ would increase rather than decrease [Ca2+]. Hypoxic vasodilation would not be 
expected from this change. 
The pump that moves Na+ out of the cell and K +  into the cell against concentration 
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FIG. 4. Model of vascular smooth muscle cell showing possible sites of energy-dependent reactions affected 
by hypoxia: calcium extrusion pump, ATP-dependent K +  channel, inositol trisphosphate (IP,) cascade, myosin 
light chain kinase phosphorylation, actomyosin .4TPase, and Na+ ,K*-ATPase (not shown). Reprinted from 
ref. 41 with permission. 
gradients is also driven by energy derived from the hydrolysis of ATP. Since this Na+ , 
K'-ATPase moves more K +  out of the cell than Na' into the cell, it is electrogenic, 
causing membrane hyperpolarization, capable of producing VSM relaxation (1 1) .  A de- 
crease in ATP concentration resulting from hypoxia would be expected to decrease pump 
activity, which would depolarize the membrane, making it more excitable. This effect 
could not be responsible for VSM relaxation. This action would be comparable to that of 
the physiologically occurring pump inhibitor, ouabain (26). This factor increases vascular 
reactivity and is a putative factor in the mechanism of hypertension. 
Another membrane transport system to be considered in this context is the ATP- 
dependent potassium channel. Potassium efflux through this channel causes hyperpolar- 
ization and, therefore, VSM relaxation. Normally, ATP inhibits this channel. The hyp- 
oxic lowering of ATP concentration would be expected to diminish the inhibition, per- 
mitting the channel activity to increase, resulting in hyperpolarization and VSM 
relaxation. The problem with this putative mechanism is that, whereas 50% hypoxic 
relaxation of contractions caused by NE or KCl occur at ATP concentrations of 0.58 and 
0.1 mM, respectively, the channel is maximally inhibited by much lower ATPase con- 
centrations (16). This evidence against the involvement of an ATP-dependent K channel 
is supported by the observation that glyburide, which blocks this channel does not alter 
hypoxic relaxation of VSM (41). 
The inositol phosphate cascade must also be considered as a site of action of hypoxia. 
The contractile response to NE utilizes this cascade, whereas that to KC1 does not. The 
involvement of this system is suggested by the observation that the contractile response to 
NE is more sensitive to hypoxia than is that to KCI (41). The inositol phosphate cascade 
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requires much energy from ATP (41) and its activity is altered in hypoxia. The sensitivity 
of the NE response to hypoxia probably reflects a failure of the inositol phosphate cascade 
in its release of calcium from the SR. 
In situ, paracrine influences arising from the parenchyma play an important role in 
hypoxic vasodilation. Hyperosmolarity , or increased potassium or CO, concentrations 
coming from the parenchymal metabolism, may contribute to this vasodilation. Adeno- 
sine is the parenchymal product that has received the most attention for this paracrine 
vasodilator role. It acts on the endothelial cell to release EDRF, which causes VSM 
relaxation by activating guanylate cyclase and thereby producing cGMP (42). 
ENDOTHELIUM 
An Endothelium-Derived Relaxing Factor-Nitric Oxide 
Furchgott and Zawadzki (23) discovered that stimulation of muscarinic receptors on 
endothelial cells triggered the release of a substance that relaxed the underlying VSM. 
This EDRF relaxes VSM by elevating cGMP levels. EDRF has been shown to stimulate 
soluble guanylate cyclase, and the possible identity of EDRF and nitric oxide was estab- 
lished (30,49). The actions of both EDRF and nitric oxide are inhibited by hemoglobin 
and potentiated by superoxide dismutase. The ultimate proof that EDRF is identical to 
nitric oxide was obtained by Palmer et al. (49). They showed that nitric oxide was 
released from endothelial cells by bradykinin in amounts that accounted for the actions of 
EDRF. Nitric oxide is produced from arginine and its formation can be blocked by the 
arginine analogue NG-monomethyl-L-arginine. This effect can be overcome by an excess 
of L-arginine (48,54). The endothelial cells have mechanisms for maintaining their in- 
tracellular concentration of arginine, including intracellular generation from L-citrulline. 
The intravenous infusion of NG-monomethyl-L-arginine into rabbits, rats, or guinea 
pigs results in a prompt rise in blood pressure that can be reversed by L-arginine (55). 
These experiments suggest that the basal, continuous release of nitric oxide from the 
endothelial cells is necessary to keep the vessels in a dilated state. The same seems to be 
true regarding human resistance vessels because intra-arterial injection of NG- 
monomethyl-L-arginine into the forearm causes prolonged vasoconstriction, reversible by 
L-arginine (67). These data led to the hypothesis that a deficiency of EDRF-nitric oxide 
release may contribute to the pathogenesis of hypertension (50,68). Data from several 
laboratories have examined endothelium-dependent relaxation in animal models of hy- 
pertension (35,39,40). Panza et al. (50) reported that endothelium-mediated vasodilation 
was impaired in patients with essential hypertension. It is possible that dysfunction of 
endothelial cells leading to decreased endothelium-dependent relaxation and/or increased 
endothelium-dependent contraction is present in human hypertension. This may contrib- 
ute to increased total peripheral resistance and may either exacerbate or causally contrib- 
ute to the hypertensive process. 
EDRF-nitric oxide not only relaxes VSM cells, but also inhibits the aggregation and 
adhesion of platelets by increasing intraplatelet concentrations of cGMP (52). This effect 
of EDRF is similar to the effect of prostacyclin, and a synergism between EDRF-nitric 
oxide and prostacyclin in preventing platelet aggregation has been described (52). 
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Endothelium-Derived Hyperpolarization Factor-EDHF 
Treatment of dog coronary artery with acetylcholine causes both relaxation and hyper- 
polarization of the VSM if the endothelium is intact (19). Neither occurs if the artery is 
denuded of its endothelium. The hyperpolarization of the VSM cell membrane results 
from an increase in potassium conductance. The action of the endothelium-derived hy- 
perpolarizing factor (EDHF) released from the endothelium can be differentiated from that 
of EDRF and nitric oxide because the hyperpolarization is much more transient than the 
vascular relaxation. Furthermore, hyperpolarization persists after the effects of EDRF 
have been prevented by treatment with methylene blue or hemoglobin (17,34). The nature 
of EDHF is not known. Although the cyclo-oxygenase pathway does not seem to be 
involved in its production since indomethacin does not affect its production (19), inhib- 
itors of the P450-dependent metabolism of arachidonic acid prevent the transient hyper- 
polarization, suggesting that EDHF may be a labile metabolite of arachidonic acid (59). 
Prostacy clin 
Prostacyclin is a major prostanoid produced by the endothelial cells. Apart from its role 
as an inhibitor of platelet aggregation, prostacyclin is also a powerful vasodilator. Both 
effects of prostacyclin are mediated through activation of adenylate cyclase, which leads 
to an increase in intracellular CAMP (63). Prostacyclin is broken down rapidly in plasma 
to the biologically inactive compound, 6-ketoprostaglandin F,a. Prostacyclin is produced 
in the endothelial cells in response to pulsatile pressure or stimuli such as bradykinin, 
thrombin, serotonin, and adenine nucleotides (10,623). Prostacyclin production is initiated 
by phospholipase A,, which releases arachidonic acid from membrane phospholipids. The 
enzyme cyclo-oxygenase converts arachidonic acid into prostacyclin endoperoxides, and 
prostacyclin synthase finally forms prostacyclin from prostaglandin H,. 
Similarly to EDRF-nitric oxide, prostacyclin is a local (paracrine) hormone that is 
effective only in the immediate proximity of the cell that releases it. On the abluminal side 
of the vessel, prostacyclin causes relaxation of the surrounding smooth muscle, and in the 
lumen it prevents platelets from clumping onto the endothelium (68). The instability of 
prostacyclin in the circulation makes it difficult to administer therapeutically. Beneficial 
effects have been demonstrated in patients with peripheral vascular disease and with 
Raynaud’s phenomenon who were given intravenous infusion of prostacyclin for several 
hours over a period of several days (20,. A constant infusion of prostacyclin has also been 
used to treat primary pulmonary hypertension (31). 
Figure 5 shows the interrelationship between prostacyclin and EDRF-nitric oxide. It 
should be stressed that the same chemical stimuli, or a change in membrane conformation 
induced by sheer stress, lead to the release of EDRF-nitric oxide and prostacyclin. For 
this reason, it has been suggested that these two substances are a common defense 
mechanism of the endothelium (ref. 68 and Fig. 5) .  
The important and complex role of products of the endothelium has recently been 
demonstrated in the regulation of corpus cavemosum smooth muscle tone. Relaxation of 
this vascular muscle allows for expansion of the lacunar spaces that compressed the 
outflow veins to cause an erection. Physiologically, this muscle is under the control of 
dilator nerves that mediate their action by acetylcholine and VIP. Recent in vitro obser- 
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FIG. 5. Stimulation of receptors on the endothelial cells by serotonin (5-HT), adenosine diphosphate (ADP), 
thrombin, bradykinin, or sheer stress leads to the release of vasoactive mediators. Prostacyclin relaxes smooth 
muscle and inhibits platelet aggregation by increasing levels of cyclic adenosine monophosphate (CAMP). 
EDRF-nitric oxide also relaxes smooth muscle and inhibits platelet aggregation, but by increasing levels of 
cyclic guanosine monophosphate (cGMP). By increasing CAMP and cGMP simultaneously, prostacyclin and 
EDRF act synergistically. Modified from ref. 68 with permission. 
vations characterized the regulation of rabbit and human corpus cavernosum smooth 
muscle (4). These studies demonstrated that relaxations of this muscle by acetylcholine, 
bradykinin, or substance P were endothelium dependent. The relaxation was accompanied 
by increased production of cGMP. It was attenuated by methylene blue (an inhibitor of 
guanylate cyclase) or by NG-monomethyl-L-arginine. Interestingly, the relaxation was 
potentiated by indomethacin, which inhibited release from the endothelium of a cyclo- 
oxygenase product of arachidonic acid metabolism that caused contraction of the smooth 
muscle of the corpus cavernosum. 
NEUROGENIC VASODILATION 
The lengthy and controversial study of neurogenic vascular control can readily be 
accounted for by the complexity of this regulatory system. In the middle of the 19th 
century, Claude Bernard described his observation that cutting the rabbit’s cervical sym- 
pathetic chain on one side caused the ear on that side to flush (7). He concluded that he 
had interrupted tonic sympathetic vasoconstrictor activity and thereby produced vasodi- 
lation. Six years later (8), he discovered vasodilator nerves when he stimulated the chorda 
tympany nerve and observed an increase in blood flow through the submaxillary gland. 
Early on, it was observed that many nerves contained both vasoconstrictor and vasodilator 
fibers. The effect of stimulating such a nerve gave an unpredictable result that depended 
on the relative numbers of each fiber being stimulated. In order to study either type of 
fiber, the effects of the other had to be blocked. Until the middle of this century, this was 
relatively simple since all neurogenic constriction was considered to be adrenergic, and all 
dilation was considered to be cholinergic. This concept changed, especially in the last 
decade when the number of established vasoactive, neurohumeral mediators increased 
exponentially. Figure 6 is a summation of the vasodilator mediators as depicted by Bevan 
and Brayden in 1987 (9). Not only is the number of mediators out of hand, but the 
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FIG. 6 .  Illustration from the 1987 review by Be\an and Brayden (9). illustrating putative neurotransmitters and 
possible sites of interactions between the different neuronal systems. In addition to the transmitters listed in this 
illustration, calcitonin gene-related peptide (cGRP) and nitric oxide (NO) are now established as vasodilators 
released from nerve terminals. 
complexity is magnified by the presynaptic influences of several of the mediators on the 
activities of other vasoactive nerves. Rather than attempting to consider each of the many 
neurohumoral, vasodilator mediators, we refer the reader to recent reviews (9,46,47). We 
will merely describe four recently studied vasodilator systems as examples of this com- 
plexity. 
NPY and CGRP 
Kawasaki et al. (33) demonstrated convincingly that neuropeptide Y (NPY) modulates 
the release of calcitonin gene-related peptide (CGRP) from CGRP-containing vasodilator 
nerves in rat mesenteric arteries. The mesenteric arterial bed was perfused at a constant 
rate with physiological salt solution (PSS) containing methoxamine, to produce an active 
vascular tone, and guanethidine was used to abolish neurogenic adrenergic constriction. 
Under these conditions, stimulation of the nerve supply to the artery produced a vasodi- 
lation that was caused by CGRP release. Treating the preparation with exogenous NPY 
prevented this vasodilation and prevented the release of CGRP. NPY treatment did not 
prevent vasodilation caused by exogenously administered CGRP. Immunoreactive histo- 
chemical examination demonstrated that NPY and CGRP are present in separate nerves in 
the adventitia. The proximity of these nerves would permit the release of CGRP to be 
regulated by NPY released from its nerves. 
Antidromic Vasodilation-Substance P 
It has been known for well over a century that stimulation of the distal end of a cut 
sensory nerve causes arteriolar dilation. Immunocytochemical studies are consistent with 
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the conclusion that substance P is synthesized in sensory ganglia and is distributed to 
nerve terminals by rapid axonal transport (12). Substance P is one of the most potent 
vasodilator compounds known, acting primarily to release EDRF. Intradermal injection of 
substance P produces a dermal flare (25). This effect of exogenous substance P, as well 
as antidromic neurogenic vasodilation, is blocked by substance P antagonists (58,66). 
Purinergic Nerves and ATP 
Burnstock and his associates ( 15) have presented extensive evidence indicating that 
ATP is released by itself or is coreleased with other mediators from nerves in the vascular 
adventitia. The potential complexity of this regulatory system was evident when we 
observed (18) that ATP could cause either contraction or relaxation when it acted directly 
on VSM. In addition, acting on the endothelial cell, it released both EDRF and an 
endothelium-derived contractile factor (EDCF), which included prostaglandins 1, and E, 
and thromboxane A,. 
Nitroxidergic Nerves 
Toda and Okamura (64,65) observed that the temporal artery (dog or monkey), de- 
nuded of its endothelium, contracted in response to nerve stimulation. The contraction 
was blocked by phentolamine, indicating that they had stimulated an adrenergic nerve. It 
was potentiated by NG-nitro-L-arginine (L-”A), a nitric oxide synthesis inhibitor. When 
the arteries were blocked by phentolamine and contracted with prostaglandin F2a, nerve 
stimulation resulted in VSM relaxation, which they established was caused by nitric oxide 
release, demonstrating a nitroxidergic nerve. 
PHARMACOLOGICAL AGENTS 
Nitrovasodilators 
Nitroglycerin and the organic nitrates are prodrugs that required conversion to an active 
intracellular moiety, nitric oxide (NO), that initiates VSM relaxation. Vasodilation of 
arteries and veins occurs when the enzyme guanylate cyclase is activated by NO, causing 
the conversion of guanosine triphosphate (GTP) to cGMP. This is the final pathway for 
vascular dilation caused by nitrovasodilators as well as by EDRF with NO as a common 
denominator (1,44). The initial step of denitration of the organic nitrates requires reduced 
thiol groups in the form of cysteine (44). During nitrate biotransformation, there is an 
obligatory role for the oxidation of SH donors, as the nitrate molecule is converted to 
nitric acid and then to NO. Continuous nitrate administration results in the loss of reduced 
SH groups in the cytoplasm and thus leads to nitrate tolerance (45). In contrast, nitro- 
prusside directly forms NO without relying on reduced SH availability, tolerance is not 
found with this compound (45). 
Needleman et al. (44,45) suggested that thiol donors such as N-acetylcysteine (NAC) 
or methionine may be effective in preventing or reversing this tolerance. A number of 
studies have shown that nitrate tolerance can be partially reversed by the addition of NAC 
or methionine (22,37) but other studies have produced negative results (29,5 1). The goals 
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of enhancing nitrate activity with respect to smooth muscle responses (e.g., angina or 
congestive heart failure) with a thiol donor hold promise for continuing clinical investi- 
gation ( 15). 
Calcium Channel Antagonists 
The calcium channel antagonists are a chemically heterogenous group of agents that 
inhibit transport of calcium ions into the VSM cells by selectively binding with vascular 
receptor sites of calcium channels. These receptor sites are associated with a major protein 
of the L class of voltage-gated channels (6). As a result of reduced calcium ion entry, 
VSM tone is reduced, producing arteriolar dilation and a reduction in total peripheral 
resistance. Using a variety of biochemical, immunologic, and pharmacologic techniques, 
it has been established that the “L” channel consists of five subunits (a l ,  a2, pl,  y and 
6). The receptor sites for calcium antagonists are within the structure of the a, subunit 
(60). Calcium antagonists exert their effects by binding to the calcium channel a1 subunit, 
probably with the highest affinity when the channel is in the depolarized or “inactivated” 
state ( 5 ) .  
Several laboratories are currently attempting to identify the specific binding sites on the 
a1 subunit (36). This should allow the development of drugs with high tissue specificity 
and favorable cardiac protective abilities. 
Potassium Channel Openers 
Selective opening of ATP-regulated K + channels leads to an outward potassium current 
causing membrane hyperpolarization, which closes voltage-operated calcium channels. 
The resultant fall in cytosolic Ca2+ reduces VSM contractile activity (57). Several chem- 
ically different compounds belong to the class of pharmacological agents referred to as 
K + channel openers. Two established vasodilators, minoxidil and diazoxide, produce part 
of their effect via the opening of vascular K+ channels. 
Other agents sharing this mechanism of action include cromakalim, lemakalim, pina- 
cidil, and nicorandil. The latter compound is also a potent stimulator of cGMP formation 
(mechanism of action of nitrates). Patch-clamp studies confirmed the presence of ATP- 
sensitive K +  channels in VSM cells isolated from rabbit mesenteric arteries (61). The 
kinetic pattern of the channel activity was found to be similar to that already described for 
ATP-sensitive K +  channels in cardiac and skeletal muscle. The conductance in smooth 
muscle cells was found to be 135 pS, which differentiated the ATP-sensitive K +  channels 
of VSM from these channels in cardiac and skeletal muscle (conductance of 4&90 pS). 
These K +  channels mediated the relaxation of arterial smooth muscle by K +  channel 
openers and these effects are inhibited by glibenclamide, a blocker of ATP-sensitive K t  
channels (57,6 I ) .  
In normotensive animals, K +  channel openers decrease the blood pressure in a dose- 
dependent manner. Similar results have been obtained in hypertensive animals (13,14). 
The effects of K +  channel openers on regional blood flow and vascular resistance have 
been explored in a number of studies. In anesthetized and conscious animals, these drugs 
increase coronary blood flow. This coronary vasodilation tends to be more pronounced in 
the epicardial regions than in the subendocardial area. Vasodilation is weaker in the brain, 
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small intestine, kidney, and skeletal muscle. This regional blood flow profile is different 
from that of calcium channel agonists, which are potent coronary, cerebral, and skeletal 
muscle vasodilators. The dilatation by Kf channel openers also differs from that of 
converting enzyme inhibitors, which preferentially dilate the renal and skeletal muscle 
vascular beds (14). 
The potential cardiovascular applications of this class of drugs are in the treatment of 
hypertension and coronary artery disease. The side effects of this group of agents are 
common to all peripheral vasodilators and include tachycardia, stimulation of plasma 
renin activity, and sodium and water retention. These effects could be minimized if K +  
channel openers are administered together with drugs possessing complementary mech- 
anisms of action such as angiotensin converting enzyme inhibitors, P-adrenoceptor an- 
tagonists, and/or diuretics. 
SUMMARY 
The mechanisms of vasorelaxation play an essential role in the regulation of blood 
pressure and in the distribution of blood flow. The ultimate determinant of vasorelaxation 
is a lowering of the concentration of ionized calcium [Ca2+Ii in the VSM cell. This review 
considered first the intracellular mechanisms involving cyclic nucleotides and hypoxia as 
causes of VSM relaxation. Most physiological and pharmacological mechanisms respon- 
sible for this relaxation are mediated by an excess production of cGMP. Important va- 
sodilator influences arise from the endothelium and from nerve terminals in the adventitia. 
Although several vasoactive factors are released from the endothelium, nitric oxide is its 
most important product. Many different neurohumoral factors that cause relaxation of 
VSM are released in the adventitia. One of them appears to be nitric oxide, duplicating 
the mechanism of the vasorelaxation from the endothelium. These two regulatory systems 
also interact when the neurohumoral agent stimulates the endothelial cell to release its 
vasoactive factors. This interaction is exemplified by the release from cholinergic nerves 
of acetylcholine, which acts on the endothelium of the lacunar spaces to produce nitric 
oxide, causing vasorelaxation of the corpus cavernosum. 
Important pharmacological vasorelaxants act through the cellular mechanisms that we 
have reviewed in connection with the physiological relaxations of VSM: nitrovasodilators 
stimulate the production of cGMP and calcium channel antagonists and potassium channel 
openers reduce the rate of calcium entry into the cell, permitting the [Ca2+li to be lowered 
by the physiological mechanisms for lowering the levels of cytosolic calcium (Fig. 1). 
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